PL1874819T3 - Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów - Google Patents

Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów

Info

Publication number: PL1874819T3
Authority: PL; Poland
Prior art keywords: stimulating factor; colony stimulating; macrophage colony; granulocyte macrophage; human granulocyte
Prior art date: 2005-04-18

Application number

PL06724392T

Other languages

English (en)

Inventor

Tobias Raum

Hepp, (Née Henckel) Julia

Eva Vieser

Silke Petsch

Steven Zeman

Andreas Wolf

Sandra Bruckmaier

Original Assignee

Amgen Res Munich Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-18

Filing date

2006-04-18

Publication date

2015-10-30

2006-04-18 Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh

2015-10-30 Publication of PL1874819T3 publication Critical patent/PL1874819T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)

PL06724392T 2005-04-18 2006-04-18 Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów PL1874819T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05008410		2005-04-18
EP06724392.3A EP1874819B1 (en)	2005-04-18	2006-04-18	Antibody neutralizers of human granulocyte macrophage colony stimulating factor
PCT/EP2006/003528 WO2006111353A2 (en)	2005-04-18	2006-04-18	Antibody neutralizers of human granulocyte macrophage colony stimulating factor

Publications (1)

Publication Number	Publication Date
PL1874819T3 true PL1874819T3 (pl)	2015-10-30

Family

ID=37115507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06724392T PL1874819T3 (pl)	2005-04-18	2006-04-18	Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów

Country Status (28)

Country	Link
US (3)	US8017748B2 (pl)
EP (2)	EP2468774A3 (pl)
JP (1)	JP5085533B2 (pl)
KR (2)	KR101704809B1 (pl)
CN (2)	CN103342751B (pl)
AU (1)	AU2006237159B2 (pl)
BR (1)	BRPI0608281B8 (pl)
CA (1)	CA2605402C (pl)
CY (1)	CY1116632T1 (pl)
DK (1)	DK1874819T3 (pl)
EA (2)	EA013162B1 (pl)
ES (1)	ES2545769T3 (pl)
HR (1)	HRP20150773T1 (pl)
HU (1)	HUE025134T2 (pl)
IL (2)	IL186486A0 (pl)
ME (1)	ME02191B (pl)
MX (1)	MX2007012569A (pl)
NO (1)	NO344249B1 (pl)
NZ (1)	NZ562093A (pl)
PL (1)	PL1874819T3 (pl)
PT (1)	PT1874819E (pl)
RS (1)	RS54127B1 (pl)
RU (2)	RU2458071C2 (pl)
SG (1)	SG161292A1 (pl)
SI (1)	SI1874819T1 (pl)
UA (1)	UA94403C2 (pl)
WO (1)	WO2006111353A2 (pl)
ZA (1)	ZA200708201B (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007012569A (es)	2005-04-18	2007-12-06	Micromet Ag	Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
JP4736037B2 (ja) *	2005-10-26	2011-07-27	株式会社イーベック	ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101395515B1 (ko)	2006-02-08	2014-05-14	모르포테크, 인크.	항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
US20080171038A1 (en) *	2006-11-08	2008-07-17	Kalobios Pharmaceuticals, Inc.	Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en)	2006-11-21	2013-03-19	Kalobios Pharmaceuticals, Inc.	Methods of treating dementia using a GM-CSF antagonist
CN101641373B (zh) *	2007-02-08	2015-02-11	默沙东公司	Dkk-1的特异性抗体
JP2010527939A (ja) *	2007-05-23	2010-08-19	シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド	中和抗体
TW200918553A (en) *	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
US8679502B2 (en) *	2007-11-13	2014-03-25	Evec Inc.	Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
TW201920257A (zh) *	2008-04-11	2019-06-01	日商中外製藥股份有限公司	重複結合複數個抗原的抗原結合分子
KR101824512B1 (ko) *	2008-04-28	2018-02-02	휴머니건, 아이엔씨.	과립구-대식세포 콜로니 자극 인자에 대한 항체
CA2717987C (en) *	2008-04-29	2018-11-13	Micromet Ag	Inhibitors of gm-csf and il-17 for therapy
RU2366422C1 (ru) *	2008-05-19	2009-09-10	Государственное учреждение Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской Академии медицинских наук (ГУ НИИ фармакологии ТНЦ СО РАМН)	Способ коррекции депрессии гранулоцитопоэза при цитостатическом воздействии
DK2376121T4 (da) *	2008-12-22	2021-08-16	Univ Melbourne	Slidgigtbehandling
EP3381471B1 (en)	2008-12-22	2024-03-20	The University of Melbourne	Pain treatment
US20120116059A1 (en) *	2009-05-05	2012-05-10	Morphosys Ag	Treatment For M Treatment For Multiple Sclerosis
SG10201609665PA (en)	2011-02-25	2017-01-27	Chugai Pharmaceutical Co Ltd	FcɣRIIb-SPECIFIC Fc ANTIBODY
BR112013033944A2 (pt)	2011-07-06	2017-12-19	Morphosys Ag	combinação sinérgica
WO2013090989A1 (en)	2011-12-22	2013-06-27	Csl Limited	Method of treating inflammatory bowel disease
WO2014004549A2 (en)	2012-06-27	2014-01-03	Amgen Inc.	Anti-mesothelin binding proteins
US9833410B2 (en)	2012-10-31	2017-12-05	Takeda Gmbh	Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) *	2012-10-31	2015-05-27	Amgen Res Munich Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US20160024200A1 (en) *	2013-03-14	2016-01-28	John Schrader	Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
WO2015028666A1 (en) *	2013-08-30	2015-03-05	Takeda Gmbh	Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis
RU2714919C2 (ru) *	2013-08-30	2020-02-21	Такеда Гмбх	Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
EP3054987B1 (en)	2013-10-11	2019-10-09	The United States of America, represented by the Secretary, Department of Health and Human Services	Tem8 antibodies and their use
WO2015103549A1 (en)	2014-01-03	2015-07-09	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
US11173208B2 (en)	2014-05-07	2021-11-16	Takeda Gmbh	Liquid formulation comprising GM-CSF neutralizing compound
US10160795B2 (en)	2014-11-14	2018-12-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to Ebola virus glycoprotein and their use
WO2016079276A1 (en) *	2014-11-21	2016-05-26	Takeda Gmbh	Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
WO2016079277A1 (en) *	2014-11-21	2016-05-26	Takeda Gmbh	Use of an anti-gm-csf antagonist in the treatment of an infectious disease
US10301377B2 (en)	2015-02-24	2019-05-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
GB201503139D0 (en) *	2015-02-25	2015-04-08	Univ Leicester	Diagnostic and therapeutic target
HRP20200583T1 (hr)	2015-03-20	2020-07-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Protutijela koja neutraliziraju gp120 i njihova upotreba
AU2016335750B2 (en)	2015-10-07	2023-05-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
GB201519331D0 (en) *	2015-11-02	2015-12-16	Glaxosmithkline Ip Dev Ltd	Treatment paradigm
EP4011911A1 (en)	2015-11-03	2022-06-15	The United States of America as represented by The Secretary Department of Health and Human Services	Neutralizing antibodies to hiv-1 gp41 and their use
WO2017192589A1 (en)	2016-05-02	2017-11-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to influenza ha and their use and identification
CN106872428A (zh) *	2017-02-07	2017-06-20	远见生物科技（上海）有限公司	一种用于检测中性粒细胞呼吸爆发功能的试剂盒
EP3580235B1 (en)	2017-02-10	2024-05-01	The United States of America, as represented by the Secretary, Department of Health and Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US10899831B2 (en)	2017-10-02	2021-01-26	Humanigen, Inc.	Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en)	2017-10-02	2021-09-28	Humanigen, Inc.	Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
CN111757744A (zh)	2017-10-02	2020-10-09	人源股份有限公司	使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
US10927168B2 (en)	2017-10-02	2021-02-23	Humanicen, Inc.	Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
JP7138896B2 (ja)	2017-10-24	2022-09-20	株式会社Asm	低包接率ポリロタキサンの製造方法
US11976109B2 (en)	2018-01-02	2024-05-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to ebola virus glycoprotein and their use
CN111971299A (zh)	2018-02-21	2020-11-20	美国政府(由卫生和人类服务部的部长所代表)	HIV-1 Env的中和抗体及其用途
CN112805301B (zh) *	2018-10-15	2023-07-21	安立玺荣生医(香港)有限公司	粒细胞-巨噬细胞集落刺激因子的抗体及其用途
US11078264B2 (en)	2018-10-17	2021-08-03	University Of Connecticut	Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
EP3883609A2 (en)	2018-12-20	2021-09-29	The United States of America, as represented by the Secretary, Department of Health and Human Services	Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
WO2020227228A2 (en)	2019-05-03	2020-11-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CN118359709A (zh)	2019-05-21	2024-07-19	佐治亚大学研究基金会有限公司	结合人类偏肺病毒融合蛋白的抗体及其用途
MX2022000174A (es)	2019-07-02	2022-05-20	Us Health	Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
WO2021204649A1 (en)	2020-04-06	2021-10-14	Glaxosmithkline Intellectual Property Development Limited	Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022132904A1 (en)	2020-12-17	2022-06-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies targeting sars-cov-2
AU2022221297A1 (en)	2021-02-09	2023-08-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies targeting the spike protein of coronaviruses
CN117396502A (zh)	2021-02-09	2024-01-12	佐治亚大学研究基金会有限公司	针对肺炎球菌抗原的人类单克隆抗体
AU2022345251A1 (en)	2021-09-17	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
CA3251161A1 (en)	2022-02-10	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that broadly target coronaviruses
WO2023192881A1 (en)	2022-03-28	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
EP4565329A1 (en)	2022-08-01	2025-06-11	The United States of America, as represented by the Secretary, Department of Health and Human Services	Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en)	2022-09-07	2024-03-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en)	2022-09-22	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024137381A1 (en)	2022-12-19	2024-06-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies for treating sars-cov-2 infection
WO2024138151A1 (en)	2022-12-22	2024-06-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
WO2024243355A1 (en)	2023-05-24	2024-11-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
WO2025014896A1 (en)	2023-07-07	2025-01-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Humanized 40h3 antibody
EP4747276A1 (en)	2023-07-21	2026-05-27	The United States of America, as represented by The Secretary, Department of Health and Human Services	Bispecific antibodies that broadly target coronaviruses
WO2025106427A1 (en)	2023-11-14	2025-05-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025117384A1 (en)	2023-12-01	2025-06-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Broadly neutralizing influenza hemagglutinin stem-directed antibodies
IL328694A (en)	2023-12-21	2026-07-01	Us Health	Broad neutralizing antibodies against SARS-COV-2 and SARS-COV variants
WO2026030473A1 (en)	2024-07-31	2026-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	West nile virus neutralizing monoclonal antibodies
WO2026128512A1 (en)	2024-12-09	2026-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies to nipah virus and their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8624899D0 (en) *	1986-10-17	1986-11-19	Sandoz Ltd	Monoclonal antibodies
US5070013A (en) *	1988-05-31	1991-12-03	Schering Corporation	Immunochemical assay for human granulocyte-macrophage colony stimulating factor
CA2060741A1 (en) *	1991-02-11	1992-08-12	Robert S. Greenfield	Gm-csf inhibiting oligopeptides
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
DE69834032T2 (de)	1997-04-23	2006-12-07	Universität Zürich	Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
CA2326389C (en)	1998-04-21	2007-01-23	Micromet Gesellschaft Fur Biomedizinische Forschung Mbh	Novel cd19xcd3 specific polypeptides and uses thereof
US7157091B1 (en) *	1999-06-18	2007-01-02	Ludwig Institute For Cancer Research	MAGE-A1 peptides presented by HLA class II molecules
WO2001058459A1 (fr) *	2000-02-14	2001-08-16	Mitsubishi Pharma Corporation	Remedes contre l'hepatite c
US20050271663A1 (en) *	2001-06-28	2005-12-08	Domantis Limited	Compositions and methods for treating inflammatory disorders
ATE444308T1 (de) *	2002-02-13	2009-10-15	Ludwig Inst Cancer Res	Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
ATE435238T1 (de) *	2004-05-05	2009-07-15	Micromet Ag	Herstellung eines einkettigen fv antikörperfragments
MX2007012569A (es) *	2005-04-18	2007-12-06	Micromet Ag	Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
ES2918209T3 (es)	2005-05-18	2022-07-14	Morphosys Ag	Anticuerpos anti-GM-CSF y usos a partir de los mismos
KR101395515B1 (ko)	2006-02-08	2014-05-14	모르포테크, 인크.	항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체

2006
- 2006-04-18 MX MX2007012569A patent/MX2007012569A/es active IP Right Grant
- 2006-04-18 KR KR1020077026929A patent/KR101704809B1/ko not_active Expired - Lifetime
- 2006-04-18 SI SI200631960T patent/SI1874819T1/sl unknown
- 2006-04-18 JP JP2008506992A patent/JP5085533B2/ja not_active Expired - Fee Related
- 2006-04-18 CN CN201310231969.5A patent/CN103342751B/zh not_active Expired - Lifetime
- 2006-04-18 HU HUE06724392A patent/HUE025134T2/en unknown
- 2006-04-18 PT PT67243923T patent/PT1874819E/pt unknown
- 2006-04-18 EA EA200702008A patent/EA013162B1/ru unknown
- 2006-04-18 HR HRP20150773TT patent/HRP20150773T1/hr unknown
- 2006-04-18 CA CA2605402A patent/CA2605402C/en not_active Expired - Lifetime
- 2006-04-18 RS RS20150497A patent/RS54127B1/sr unknown
- 2006-04-18 EP EP12159883A patent/EP2468774A3/en not_active Ceased
- 2006-04-18 US US11/918,368 patent/US8017748B2/en active Active
- 2006-04-18 WO PCT/EP2006/003528 patent/WO2006111353A2/en not_active Ceased
- 2006-04-18 KR KR1020157020152A patent/KR20150091193A/ko not_active Abandoned
- 2006-04-18 PL PL06724392T patent/PL1874819T3/pl unknown
- 2006-04-18 UA UAA200712125A patent/UA94403C2/ru unknown
- 2006-04-18 BR BRPI0608281A patent/BRPI0608281B8/pt active IP Right Grant
- 2006-04-18 SG SG201002699-5A patent/SG161292A1/en unknown
- 2006-04-18 ES ES06724392.3T patent/ES2545769T3/es not_active Expired - Lifetime
- 2006-04-18 CN CN2006800188584A patent/CN101184777B/zh not_active Expired - Lifetime
- 2006-04-18 EP EP06724392.3A patent/EP1874819B1/en not_active Expired - Lifetime
- 2006-04-18 AU AU2006237159A patent/AU2006237159B2/en not_active Expired
- 2006-04-18 RU RU2007138341/10A patent/RU2458071C2/ru active
- 2006-04-18 DK DK06724392.3T patent/DK1874819T3/en active
- 2006-04-18 EA EA200901500A patent/EA017420B9/ru unknown
- 2006-04-18 NZ NZ562093A patent/NZ562093A/en unknown
- 2006-04-18 ME MEP-2015-111A patent/ME02191B/me unknown
2007
- 2007-09-20 ZA ZA200708201A patent/ZA200708201B/en unknown
- 2007-10-08 IL IL186486A patent/IL186486A0/en not_active IP Right Cessation
- 2007-11-12 NO NO20075802A patent/NO344249B1/no unknown
2011
- 2011-08-04 US US13/198,558 patent/US9067993B2/en active Active
2012
- 2012-04-20 RU RU2012115683/10A patent/RU2012115683A/ru not_active Application Discontinuation
- 2012-06-14 IL IL220412A patent/IL220412A/en active IP Right Grant
2015
- 2015-05-21 US US14/718,923 patent/US10138297B2/en active Active
- 2015-08-20 CY CY20151100731T patent/CY1116632T1/el unknown

Also Published As

Publication number	Publication date
CA2605402C (en)	2017-05-23
SG161292A1 (en)	2010-05-27
NO20075802L (no)	2008-01-10
BRPI0608281B8 (pt)	2021-05-25
KR20080005962A (ko)	2008-01-15
BRPI0608281A2 (pt)	2009-12-15
EP1874819B1 (en)	2015-05-27
IL220412A (en)	2017-04-30
US9067993B2 (en)	2015-06-30
IL186486A0 (en)	2008-01-20
DK1874819T3 (en)	2015-08-31
NO344249B1 (no)	2019-10-21
BRPI0608281B1 (pt)	2020-01-28
JP5085533B2 (ja)	2012-11-28
IL220412A0 (en)	2012-07-31
UA94403C2 (ru)	2011-05-10
HRP20150773T1 (hr)	2015-08-28
EP2468774A3 (en)	2013-01-02
AU2006237159A1 (en)	2006-10-26
EA017420B9 (ru)	2013-03-29
EP2468774A2 (en)	2012-06-27
EA013162B1 (ru)	2010-02-26
CN101184777A (zh)	2008-05-21
KR20150091193A (ko)	2015-08-07
RU2012115683A (ru)	2013-10-27
US20120009195A1 (en)	2012-01-12
MX2007012569A (es)	2007-12-06
US20090297532A1 (en)	2009-12-03
CY1116632T1 (el)	2017-03-15
HK1112003A1 (en)	2008-08-22
PT1874819E (pt)	2015-09-17
WO2006111353A2 (en)	2006-10-26
RS54127B1 (sr)	2015-12-31
NZ562093A (en)	2011-01-28
JP2008536505A (ja)	2008-09-11
US8017748B2 (en)	2011-09-13
CA2605402A1 (en)	2006-10-26
SI1874819T1 (sl)	2015-09-30
CN103342751B (zh)	2015-12-23
HUE025134T2 (en)	2016-01-28
ME02191B (me)	2016-02-20
EA200702008A1 (ru)	2008-06-30
ES2545769T3 (es)	2015-09-15
WO2006111353A3 (en)	2007-04-19
KR101704809B1 (ko)	2017-02-08
CN101184777B (zh)	2013-07-17
RU2007138341A (ru)	2009-05-27
EA017420B1 (ru)	2012-12-28
AU2006237159B2 (en)	2011-03-24
RU2458071C2 (ru)	2012-08-10
HK1190161A1 (zh)	2014-06-27
EP1874819A2 (en)	2008-01-09
CN103342751A (zh)	2013-10-09
EA200901500A1 (ru)	2010-10-29
US10138297B2 (en)	2018-11-27
US20160130338A1 (en)	2016-05-12
ZA200708201B (en)	2008-07-30

Publication	Publication Date	Title
SI1874819T1 (sl)	2015-09-30	Protitelesni nevtralizatorji humanega faktorja stimulacije kolonij granulocitov makrofagov
IL184506A0 (en)	2007-10-31	Glycopegylated granulocyte colony stimulating factor
LTPA2018010I1 (lt)	2018-05-25	Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
IL211684A0 (en)	2011-06-30	Antibodies against human il 17 and uses thereof
SG10201500140VA (en)	2015-03-30	Human antibodies against human tissue factor
IL187375A0 (en)	2008-02-09	Anti-gm-csf antibodies and uses therefor
ZA200807278B (en)	2009-05-27	Antibodies against human IL-22 and uses therefor
IL185747A0 (en)	2008-01-06	Use of supplemental assignments
IL184036A0 (en)	2007-10-31	Preparation of rosuvastatin
IL193604A0 (en)	2011-08-01	Methods of using antibodies against human il-22
ZA201001903B (en)	2010-11-24	Use of human cells of myeloid leukaemia for expression of antibodies
IL187303A0 (en)	2008-04-13	Methods of prepering 3 - cyano - quinolines and intermediates made thereby
PT2532679T (pt)	2017-07-18	Anticorpos humanos contra il13 e utilizações terapêuticas
ZA200906516B (en)	2010-05-26	Novel human anti-R7V antibodies and uses thereof
IL185097A0 (en)	2007-12-03	Tissue specific expression of antibodies in chickens
EP1896081A4 (en)	2011-05-25	HUMAN FACTOR ISOFORMS OF STIMULATION OF GRANULAR COLONIES
IL187948A0 (en)	2008-03-20	Preparation of rosuvastatin
GB0509671D0 (en)	2005-06-15	Analysis of wood
GB0508356D0 (en)	2005-06-01	Materials and methods relating to the diagnosis of cancer
GB0715133D0 (en)	2007-09-12	Granulocyte colony stimulating factor
GB0724013D0 (en)	2008-01-23	Granulocyte colony stimulating factor
TWI317830B (en)	2009-12-01	Structure of back cover
TWM291594U (en)	2006-06-01	Improved structure of transformer
GB0605209D0 (en)	2006-04-26	Examination chair
GB0519207D0 (en)	2005-10-26	Double sunbed